Gökhan Burul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gökhan Burul has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Tahir Alper Cinli
Department of Hematology, Başakşehir Çam and Sakura City Hospital, 34480 Istanbul, Turkey
4 shared publications - Hasan Göze
Department of Hematology, Basaksehir Cam and Sakura City Hospital, Istanbul, Türkiye
3 shared publications - Istemi Serin
Department of Hematology, Başakşehir Çam and Sakura City Hospital, 34480 Istanbul, Turkey
3 shared publications İsTemi Serin
Department of Hematology, İstanbul Başakşehir Çam and Sakura City Hospital, Basaksehir, Turkey
3 shared publications- Mesut Ayer
Department of Hematology, Başakşehir Çam and Sakura City Hospital, 34480 Istanbul, Turkey
3 shared publications - Büşra Tuğçe Akman
Department of Hematology, Başakşehir Çam and Sakura City Hospital, 34480 Istanbul, Turkey
2 shared publications
Latest Publications
- 6 October 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 62
Early-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation
- 6 October 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 62
Early-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation
- Open Access
Integrated Prognostic Modelling with the CALLY Index and Interim PET/CT in Hodgkin Lymphoma
Background/Objectives: Interim 18F-FDG PET/CT is the most powerful prognostic tool in Hodgkin lymphoma but is only available after 2 cycles and does not guide initial treatment. The C-reactive protein-albumin-lymphocyte (CALLY) index is a novel composite index of inflammation, nutrition, and immunity, measurable at diagnosis, but has not been studied in Hodgkin lymphoma (HL). We tested whether baseline CALLY could predict interim PET response and survival and whether combining the two provides additional information over either alone. Methods: A retrospective study of 180 consecutive patients with newly diagnosed Hodgkin lymphoma at a single center was performed. CALLY was defined as albumin (g/L) × lymphocytes (×109/L)/CRP (mg/L). Interim PET after two cycles was scored using the Deauville scale (4–5 positive). The endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median follow-up was 30.5 months, 32 patients had a PFS event, and 16 died. Interim PET was positive in 31/163 patients (19.0%). Baseline CALLY was lower in PET-positive patients compared with PET-negative patients (median 1.16 vs. 3.34; p = 0.022; area under the curve 0.635, modest discrimination). Interim PET positivity (29.8% vs. 13.0%; OR 2.84, 95% CI 1.26–6.42), 24-month PFS (66.9% vs. 89.8%; p = 0.001) and OS (84.8% vs. 95.5%; p = 0.022) were reduced below a Youden-derived threshold of 1.5. CALLY was not independently prognostic after adjustment for interim PET (PFS hazard ratio [HR] 1.86, 95% CI 0.79–4.37; p = 0.157). A three-tier exploratory model combining both factors separated 24-month PFS into 94.5% (n = 87), 79.6% (n = 53), and 41.2% (n = 17) (p < 0.001; high- vs. low-risk HR 9.48, 95% CI 3.59–25.04), although the intermediate tier was not statistically different from the low-risk tier. Conclusions: In this cohort, baseline CALLY provides a low-cost pre-treatment correlate of early metabolic response and outcome, with numerically greater discrimination than the International Prognostic Score. Its prognostic signal seems largely mediated through the interim PET response, and therefore it should complement, not replace, interim response assessment. Discrimination was modest, and the integrated model is exploratory and requires prospective multicenter validation in contemporary protocols before clinical use.
Open AccessIntegrated Prognostic Modelling with the CALLY Index and Interim PET/CT in Hodgkin Lymphoma
Background/Objectives: Interim 18F-FDG PET/CT is the most powerful prognostic tool in Hodgkin lymphoma but is only available after 2 cycles and does not guide initial treatment. The C-reactive protein-albumin-lymphocyte (CALLY) index is a novel composite index of inflammation, nutrition, and immunity, measurable at diagnosis, but has not been studied in Hodgkin lymphoma (HL). We tested whether baseline CALLY could predict interim PET response and survival and whether combining the two provides additional information over either alone. Methods: A retrospective study of 180 consecutive patients with newly diagnosed Hodgkin lymphoma at a single center was performed. CALLY was defined as albumin (g/L) × lymphocytes (×109/L)/CRP (mg/L). Interim PET after two cycles was scored using the Deauville scale (4–5 positive). The endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median follow-up was 30.5 months, 32 patients had a PFS event, and 16 died. Interim PET was positive in 31/163 patients (19.0%). Baseline CALLY was lower in PET-positive patients compared with PET-negative patients (median 1.16 vs. 3.34; p = 0.022; area under the curve 0.635, modest discrimination). Interim PET positivity (29.8% vs. 13.0%; OR 2.84, 95% CI 1.26–6.42), 24-month PFS (66.9% vs. 89.8%; p = 0.001) and OS (84.8% vs. 95.5%; p = 0.022) were reduced below a Youden-derived threshold of 1.5. CALLY was not independently prognostic after adjustment for interim PET (PFS hazard ratio [HR] 1.86, 95% CI 0.79–4.37; p = 0.157). A three-tier exploratory model combining both factors separated 24-month PFS into 94.5% (n = 87), 79.6% (n = 53), and 41.2% (n = 17) (p < 0.001; high- vs. low-risk HR 9.48, 95% CI 3.59–25.04), although the intermediate tier was not statistically different from the low-risk tier. Conclusions: In this cohort, baseline CALLY provides a low-cost pre-treatment correlate of early metabolic response and outcome, with numerically greater discrimination than the International Prognostic Score. Its prognostic signal seems largely mediated through the interim PET response, and therefore it should complement, not replace, interim response assessment. Discrimination was modest, and the integrated model is exploratory and requires prospective multicenter validation in contemporary protocols before clinical use.
- Open Access
- 28 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6686
Is Baseline PET/CT-Derived Metabolic Tumor Burden Associated with Treatment Response and Survival in Hodgkin Lymphoma?
Background/Objectives: Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) provide quantitative assessments of metabolically active tumor burden; however, their prognostic value in Hodgkin lymphoma (HL) remains uncertain. This study evaluated the associations of baseline PET/CT-derived MTV and TLG with clinical disease characteristics, treatment response, progression-free survival (PFS), and overall survival (OS) in patients with classical HL. Methods: This retrospective single-center study included 105 adults diagnosed with classical HL between July 2020 and April 2023. Baseline PET/CT images were analyzed using LIFEx 7.1.0. Volumes of interest were delineated using a fixed threshold of 41% of SUVmax. Total MTV and TLG were calculated by summing the values of all FDG-avid lesions. Survival outcomes were evaluated using Kaplan–Meier analysis, the log-rank test, and Cox proportional hazards regression. Results: The median age was 33 years, and the median follow-up was 24 months. Higher MTV and TLG were significantly associated with advanced-stage disease, high International Prognostic Score, B symptoms, bulky disease, and extranodal involvement. Higher MTV was associated with a lower end-of-treatment response rate, whereas higher TLG was associated with lower interim and end-of-treatment response rates. Disease progression occurred in 19 patients, and 11 patients died. Compared with patients with MTV < 249, those with MTV ≥ 249 had numerically higher hazards of progression (HR = 2.18, 95% CI: 0.88–5.40; p = 0.09) and death (HR = 1.21, 95% CI: 0.37–3.96; p = 0.75). Compared with patients with TLG < 1252, those with TLG ≥ 1252 had a numerically higher hazard of progression (HR = 1.53, 95% CI: 0.61–3.86; p = 0.37) but a lower hazard of death (HR = 0.56, 95% CI: 0.17–1.85; p = 0.34). However, all confidence intervals included 1, and none of these differences reached statistical significance. Conclusions: Baseline MTV and TLG reflect disease burden and are associated with treatment response in classical HL. However, neither parameter was significantly associated with PFS or OS in this cohort. Their potential value as survival prognostic biomarkers requires confirmation in larger prospective studies with longer follow-up.
- 28 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6686
Open AccessIs Baseline PET/CT-Derived Metabolic Tumor Burden Associated with Treatment Response and Survival in Hodgkin Lymphoma?
Background/Objectives: Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) provide quantitative assessments of metabolically active tumor burden; however, their prognostic value in Hodgkin lymphoma (HL) remains uncertain. This study evaluated the associations of baseline PET/CT-derived MTV and TLG with clinical disease characteristics, treatment response, progression-free survival (PFS), and overall survival (OS) in patients with classical HL. Methods: This retrospective single-center study included 105 adults diagnosed with classical HL between July 2020 and April 2023. Baseline PET/CT images were analyzed using LIFEx 7.1.0. Volumes of interest were delineated using a fixed threshold of 41% of SUVmax. Total MTV and TLG were calculated by summing the values of all FDG-avid lesions. Survival outcomes were evaluated using Kaplan–Meier analysis, the log-rank test, and Cox proportional hazards regression. Results: The median age was 33 years, and the median follow-up was 24 months. Higher MTV and TLG were significantly associated with advanced-stage disease, high International Prognostic Score, B symptoms, bulky disease, and extranodal involvement. Higher MTV was associated with a lower end-of-treatment response rate, whereas higher TLG was associated with lower interim and end-of-treatment response rates. Disease progression occurred in 19 patients, and 11 patients died. Compared with patients with MTV < 249, those with MTV ≥ 249 had numerically higher hazards of progression (HR = 2.18, 95% CI: 0.88–5.40; p = 0.09) and death (HR = 1.21, 95% CI: 0.37–3.96; p = 0.75). Compared with patients with TLG < 1252, those with TLG ≥ 1252 had a numerically higher hazard of progression (HR = 1.53, 95% CI: 0.61–3.86; p = 0.37) but a lower hazard of death (HR = 0.56, 95% CI: 0.17–1.85; p = 0.34). However, all confidence intervals included 1, and none of these differences reached statistical significance. Conclusions: Baseline MTV and TLG reflect disease burden and are associated with treatment response in classical HL. However, neither parameter was significantly associated with PFS or OS in this cohort. Their potential value as survival prognostic biomarkers requires confirmation in larger prospective studies with longer follow-up.
- Open Access
- 10 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6179
Comparative Prognostic Performance of Nutritional Indices in Acute Myeloid Leukemia
Background/Objectives: Malnutrition adversely affects the clinical course of acute myeloid leukemia (AML), yet comparative data on objective nutritional indices remain limited. Methods: This study evaluated the prognostic performance of four indices—Controlling Nutritional Status (CONUT), Simple CONUT, Prognostic Nutritional Index (PNI), and Nutritional Risk Index (NRI)—on overall survival (OS) alongside the European LeukemiaNet (ELN) 2022 risk classification. Pre-treatment parameters of 236 newly diagnosed AML patients were retrospectively analyzed using Receiver Operating Characteristic (ROC) curves and multivariate Cox regression models. Results: In ROC analysis, only NRI demonstrated significant discriminative performance in predicting OS (Area Under the Curve = 0.637, p < 0.001), whereas CONUT, Simple CONUT, and PNI lacked statistical significance. Patients with low NRI scores had significantly worse survival than the high NRI group (median OS: 16.8 months versus not reached, p = 0.004), particularly within the ELN favorable risk category (2-year OS: 59.6% versus 93.5%, p = 0.022). Multivariate analysis established NRI as an independent predictor of mortality (Hazard Ratio = 0.967, p = 0.009) alongside age and ELN risk. Conclusions: In conclusion, NRI outperforms other nutritional indices and serves as an independent prognostic factor in AML, offering a more holistic and effective approach to clinical risk stratification.
- 10 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6179
Open AccessComparative Prognostic Performance of Nutritional Indices in Acute Myeloid Leukemia
Background/Objectives: Malnutrition adversely affects the clinical course of acute myeloid leukemia (AML), yet comparative data on objective nutritional indices remain limited. Methods: This study evaluated the prognostic performance of four indices—Controlling Nutritional Status (CONUT), Simple CONUT, Prognostic Nutritional Index (PNI), and Nutritional Risk Index (NRI)—on overall survival (OS) alongside the European LeukemiaNet (ELN) 2022 risk classification. Pre-treatment parameters of 236 newly diagnosed AML patients were retrospectively analyzed using Receiver Operating Characteristic (ROC) curves and multivariate Cox regression models. Results: In ROC analysis, only NRI demonstrated significant discriminative performance in predicting OS (Area Under the Curve = 0.637, p < 0.001), whereas CONUT, Simple CONUT, and PNI lacked statistical significance. Patients with low NRI scores had significantly worse survival than the high NRI group (median OS: 16.8 months versus not reached, p = 0.004), particularly within the ELN favorable risk category (2-year OS: 59.6% versus 93.5%, p = 0.022). Multivariate analysis established NRI as an independent predictor of mortality (Hazard Ratio = 0.967, p = 0.009) alongside age and ELN risk. Conclusions: In conclusion, NRI outperforms other nutritional indices and serves as an independent prognostic factor in AML, offering a more holistic and effective approach to clinical risk stratification.
- 25 July 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 44
HIV-negative KSHV/HHV8-associated multicentric Castleman disease with concurrent Kaposi sarcoma and POEMS-like manifestations
Introduction Castleman disease (CD) is a heterogeneous lymphoproliferative disorder with unicentric and multicentric forms. Multicentric CD (MCD) is etiologically classified into idiopathic MCD (iMCD), POEMS-associated MCD, and Kaposi sarcoma-associated herpesvirus (KSHV/HHV-8)-associated MCD, and it typically presents with systemic inflammation. KSHV/HHV-8-associated MCD is most commonly seen in HIV-positive patients, although it may rarely occur in HIV-negative individuals. Case Presentation We report a case of a 65-year-old HIV-negative woman diagnosed with mixed-type KSHV/HHV-8-associated MCD accompanied by Kaposi sarcoma and POEMS-like clinical features. The patient presented with generalized lymphadenopathy, splenomegaly, cytopenias, hypercalcemia, and monoclonal IgG lambda gammopathy. PET-CT revealed widespread hypermetabolic lymphadenopathy and a sclerotic bone lesion in the left humerus. Bone marrow examination was normocellular and showed polytypic plasma cell proliferation. Lymph node biopsy demonstrated HHV-8 (LANA-1) positivity consistent with mixed-type MCD and Kaposi sarcoma. HHV-8 DNA positivity was also confirmed. Conclusion The patient was treated with a regimen including daratumumab, bortezomib, cyclophosphamide, and dexamethasone, achieving a clinical and hematologic response after the third cycle. This case highlights that KSHV/HHV-8-associated MCD may occur in HIV-negative individuals and may present concurrently with Kaposi sarcoma and POEMS-like manifestations, representing a rare diagnostic challenge.
- 25 July 2026
- Published by Springer Nature in Journal of Hematopathology
- Vol. 19 (1) , 44
HIV-negative KSHV/HHV8-associated multicentric Castleman disease with concurrent Kaposi sarcoma and POEMS-like manifestations
Introduction Castleman disease (CD) is a heterogeneous lymphoproliferative disorder with unicentric and multicentric forms. Multicentric CD (MCD) is etiologically classified into idiopathic MCD (iMCD), POEMS-associated MCD, and Kaposi sarcoma-associated herpesvirus (KSHV/HHV-8)-associated MCD, and it typically presents with systemic inflammation. KSHV/HHV-8-associated MCD is most commonly seen in HIV-positive patients, although it may rarely occur in HIV-negative individuals. Case Presentation We report a case of a 65-year-old HIV-negative woman diagnosed with mixed-type KSHV/HHV-8-associated MCD accompanied by Kaposi sarcoma and POEMS-like clinical features. The patient presented with generalized lymphadenopathy, splenomegaly, cytopenias, hypercalcemia, and monoclonal IgG lambda gammopathy. PET-CT revealed widespread hypermetabolic lymphadenopathy and a sclerotic bone lesion in the left humerus. Bone marrow examination was normocellular and showed polytypic plasma cell proliferation. Lymph node biopsy demonstrated HHV-8 (LANA-1) positivity consistent with mixed-type MCD and Kaposi sarcoma. HHV-8 DNA positivity was also confirmed. Conclusion The patient was treated with a regimen including daratumumab, bortezomib, cyclophosphamide, and dexamethasone, achieving a clinical and hematologic response after the third cycle. This case highlights that KSHV/HHV-8-associated MCD may occur in HIV-negative individuals and may present concurrently with Kaposi sarcoma and POEMS-like manifestations, representing a rare diagnostic challenge.
- Open Access
- 17 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4703
Comparative Prognostic Performance of Nutritional and Inflammatory Indices in Diffuse Large B-Cell Lymphoma
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Despite advances in immunochemotherapy, approximately 30–40% of patients experience relapsed or refractory disease. Nutritional and inflammatory status, reflected by composite indices, may independently influence clinical outcomes. However, the prognostic value of the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), and Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score has not been well established in DLBCL patients treated with rituximab-based regimens. Methods: We retrospectively analyzed 192 patients with newly diagnosed DLBCL who received at least three cycles of R-CHOP or R-EPOCH at Başakşehir Çam and Sakura City Hospital between January 2020 and January 2026. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal cutoff values. Kaplan–Meier analysis with log-rank testing and univariable/multivariable Cox proportional hazards regression analyses were used to evaluate the prognostic impact of the PNI, GNRI, and HALP on overall survival (OS) and progression-free survival (PFS). Results: Among the six indices evaluated (PNI, GNRI, HALP, SII, ALI, and CAR), the PNI demonstrated the highest discriminatory ability for OS (AUC = 0.734, p = 0.001), followed by the HALP (AUC = 0.671, p = 0.020) and GNRI (AUC = 0.668, p = 0.022). The optimal cutoff values were ≤46.45 for the PNI, ≤46.91 for the GNRI, and ≤223.95 for HALP. Low values of all three indices were significantly associated with elevated LDH levels, advanced Ann Arbor stage, and higher IPI category. Kaplan–Meier analysis demonstrated significantly inferior OS in the low PNI (52.8 ± 2.6 vs. 67.1 ± 1.2 months, p = 0.001), low GNRI (49.5 ± 3.1 vs. 66.0 ± 1.4 months, p = 0.001), and low HALP (58.8 ± 2.8 vs. 64.9 ± 1.2 months, p = 0.005) groups. In separate multivariable Cox models adjusted for sex and IPI, the PNI (HR = 0.216, p = 0.009), HALP (HR = 0.276, p = 0.031), and GNRI (HR = 0.294, p = 0.011) remained independently associated with OS. No significant association was observed between these indices and PFS. Conclusions: The PNI, GNRI, and HALP are independent prognostic markers in patients with DLBCL treated with rituximab-based regimens. These readily available and inexpensive baseline indices may complement the IPI in identifying patients at higher risk of adverse outcomes and support risk stratification at diagnosis.
- 17 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4703
Open AccessComparative Prognostic Performance of Nutritional and Inflammatory Indices in Diffuse Large B-Cell Lymphoma
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Despite advances in immunochemotherapy, approximately 30–40% of patients experience relapsed or refractory disease. Nutritional and inflammatory status, reflected by composite indices, may independently influence clinical outcomes. However, the prognostic value of the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), and Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score has not been well established in DLBCL patients treated with rituximab-based regimens. Methods: We retrospectively analyzed 192 patients with newly diagnosed DLBCL who received at least three cycles of R-CHOP or R-EPOCH at Başakşehir Çam and Sakura City Hospital between January 2020 and January 2026. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal cutoff values. Kaplan–Meier analysis with log-rank testing and univariable/multivariable Cox proportional hazards regression analyses were used to evaluate the prognostic impact of the PNI, GNRI, and HALP on overall survival (OS) and progression-free survival (PFS). Results: Among the six indices evaluated (PNI, GNRI, HALP, SII, ALI, and CAR), the PNI demonstrated the highest discriminatory ability for OS (AUC = 0.734, p = 0.001), followed by the HALP (AUC = 0.671, p = 0.020) and GNRI (AUC = 0.668, p = 0.022). The optimal cutoff values were ≤46.45 for the PNI, ≤46.91 for the GNRI, and ≤223.95 for HALP. Low values of all three indices were significantly associated with elevated LDH levels, advanced Ann Arbor stage, and higher IPI category. Kaplan–Meier analysis demonstrated significantly inferior OS in the low PNI (52.8 ± 2.6 vs. 67.1 ± 1.2 months, p = 0.001), low GNRI (49.5 ± 3.1 vs. 66.0 ± 1.4 months, p = 0.001), and low HALP (58.8 ± 2.8 vs. 64.9 ± 1.2 months, p = 0.005) groups. In separate multivariable Cox models adjusted for sex and IPI, the PNI (HR = 0.216, p = 0.009), HALP (HR = 0.276, p = 0.031), and GNRI (HR = 0.294, p = 0.011) remained independently associated with OS. No significant association was observed between these indices and PFS. Conclusions: The PNI, GNRI, and HALP are independent prognostic markers in patients with DLBCL treated with rituximab-based regimens. These readily available and inexpensive baseline indices may complement the IPI in identifying patients at higher risk of adverse outcomes and support risk stratification at diagnosis.
- 13 January 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (2) , e70167
Macrophage Activation Syndrome Following Vaccination After HSCT
- 13 January 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (2) , e70167
Macrophage Activation Syndrome Following Vaccination After HSCT
- Open Access
- 7 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (12) , 3375
IL-1 Inhibitors in the Treatment of Familial Mediterranean Fever: Treatment Indications and Clinical Features in a Large Real-World Cohort
Background: The accruing evidence about the efficacy of anti-IL-1 agents in Familial Mediterranean Fever (FMF) patients led to their widespread off-label use. Therefore, identifying precise indications and clinical characteristics of IL-1i-warranting patients are important. This study investigated the clinical characteristics and treatment indications of patients with FMF requiring interleukin 1 inhibition therapy (IL-1i). Methods: Hospital records of FMF patients attending a tertiary care center at the Department of Rheumatology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital were retrospectively analyzed. Data on symptoms and disease manifestations, age of symptom onset, time to diagnosis, MEFV variants, type of treatment, and their indications were collected. Results: Between June 2020 and March 2023, 312 FMF patients were identified. The mean age at the onset of symptoms was 14.0, and the mean time to diagnosis was 11.9 years. In total, 87.1% of patients were receiving colchicine monotherapy, while the remaining 11.8% warranted IL-1i. Clinical symptoms and flare manifestations did not show a significant difference between the two groups. However, patients receiving IL-1i started having symptoms at younger age (11.5 vs. 14.5, p = 0.042) and time to diagnosis was longer (18.2 vs. 11.0, p < 0.01). M694V homozygosity was more common in patients receiving IL-1i. Indications for patients receiving IL-1i were colchicine resistance (8.0%), secondary amyloidosis (5.1%), and colchicine intolerance (2.2%). Conclusions: This study shows that a subset of FMF patients, particularly those with a more severe phenotype with an earlier disease onset and M694V homozygosity, require IL-1i treatment despite the overall good efficacy and tolerability of colchicine, primarily due to colchicine resistance, intolerance, or complications such as amyloidosis.
- 7 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (12) , 3375
Open AccessIL-1 Inhibitors in the Treatment of Familial Mediterranean Fever: Treatment Indications and Clinical Features in a Large Real-World Cohort
Background: The accruing evidence about the efficacy of anti-IL-1 agents in Familial Mediterranean Fever (FMF) patients led to their widespread off-label use. Therefore, identifying precise indications and clinical characteristics of IL-1i-warranting patients are important. This study investigated the clinical characteristics and treatment indications of patients with FMF requiring interleukin 1 inhibition therapy (IL-1i). Methods: Hospital records of FMF patients attending a tertiary care center at the Department of Rheumatology, University of Health Sciences, Basaksehir Cam and Sakura City Hospital were retrospectively analyzed. Data on symptoms and disease manifestations, age of symptom onset, time to diagnosis, MEFV variants, type of treatment, and their indications were collected. Results: Between June 2020 and March 2023, 312 FMF patients were identified. The mean age at the onset of symptoms was 14.0, and the mean time to diagnosis was 11.9 years. In total, 87.1% of patients were receiving colchicine monotherapy, while the remaining 11.8% warranted IL-1i. Clinical symptoms and flare manifestations did not show a significant difference between the two groups. However, patients receiving IL-1i started having symptoms at younger age (11.5 vs. 14.5, p = 0.042) and time to diagnosis was longer (18.2 vs. 11.0, p < 0.01). M694V homozygosity was more common in patients receiving IL-1i. Indications for patients receiving IL-1i were colchicine resistance (8.0%), secondary amyloidosis (5.1%), and colchicine intolerance (2.2%). Conclusions: This study shows that a subset of FMF patients, particularly those with a more severe phenotype with an earlier disease onset and M694V homozygosity, require IL-1i treatment despite the overall good efficacy and tolerability of colchicine, primarily due to colchicine resistance, intolerance, or complications such as amyloidosis.